Yelena Ustoyev

A phase 1b food effect study of the first-in-class, oral, selective inhibitor of nuclear export (SINE) selinexor (KPT-330) in patients (pts) with advanced sarcomas.

G. Schwartz, M. Gounder, A. Razak, 2014 .

Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.

L. Qin, C. Antonescu, S. Singer, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cancer and the Immune System: The History and Background of Immunotherapy.

M. Abbott, Yelena Ustoyev, 2019, Seminars in oncology nursing.

Combined KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas.

J. Erinjeri, G. Schwartz, A. Shoushtari, 2014 .

Phase II trial of the CDK4 inhibitor PD0332991 in CDK4-amplified liposarcoma.

L. Qin, C. Antonescu, S. Singer, 2012 .

Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.

L. Qin, C. Antonescu, S. Singer, 2013, Journal of Clinical Oncology.